PYC Therapeutics (ASX:PYC) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:PYC PYC Therapeutics Ltd ASX:PYC
33 GF Score
Price A$1.67
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Net Loan?

Net Loan only applies to banks and insurance companies.

ASX:PYC
33GF Score
PYC Therapeutics Ltd ASX:PYC
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
33GF Score

Get the complete analysis for ASX:PYC

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.67
Price